These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 28299611)

  • 21. Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study.
    Dechartres A; Boutron I; Trinquart L; Charles P; Ravaud P
    Ann Intern Med; 2011 Jul; 155(1):39-51. PubMed ID: 21727292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Symmetry analysis for monitoring safety of newly marketed drugs.
    Kubota K
    Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):349-51. PubMed ID: 26440748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigating patient exclusion bias in meta-analysis.
    Tierney JF; Stewart LA
    Int J Epidemiol; 2005 Feb; 34(1):79-87. PubMed ID: 15561753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adaptive and repeated cumulative meta-analyses of safety data during a new drug development process.
    Quan H; Ma Y; Zheng Y; Cho M; Lorenzato C; Hecquet C
    Pharm Stat; 2015; 14(3):161-71. PubMed ID: 25612310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unpublished data can be of value in systematic reviews of adverse effects: methodological overview.
    Golder S; Loke YK; Bland M
    J Clin Epidemiol; 2010 Oct; 63(10):1071-81. PubMed ID: 20457510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SAFETY PROFILE OF OCRIPLASMIN FOR SYMPTOMATIC VITREOMACULAR ADHESION: A Comprehensive Analysis of Premarketing and Postmarketing Experiences.
    Hahn P; Chung MM; Flynn HW; Huang SS; Kim JE; Mahmoud TH; Sadda SR; Dugel PU
    Retina; 2015 Jun; 35(6):1128-34. PubMed ID: 25635575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primer: strengths and weaknesses of meta-analysis.
    Finckh A; Tramèr MR
    Nat Clin Pract Rheumatol; 2008 Mar; 4(3):146-52. PubMed ID: 18227829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Meta-analyses or megatrials: same level of proof?].
    Mismetti P; Cucherat M; Laporte S
    Presse Med; 2007 Mar; 36(3 Pt 2):524-30. PubMed ID: 17275251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Publication bias in dermatology systematic reviews and meta-analyses.
    Atakpo P; Vassar M
    J Dermatol Sci; 2016 May; 82(2):69-74. PubMed ID: 26925817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Methods for drug safety monitoring: yesterday, today, tomorrow].
    Nazimkin KE; Ovchinnikova EA; Zhuravleva MV
    Antibiot Khimioter; 2007; 52(7-8):41-52. PubMed ID: 18986024
    [No Abstract]   [Full Text] [Related]  

  • 31. Meta-analysis of clinical trial safety data in a drug development program: answers to frequently asked questions.
    Berlin JA; Crowe BJ; Whalen E; Xia HA; Koro CE; Kuebler J
    Clin Trials; 2013 Feb; 10(1):20-31. PubMed ID: 23171499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Quantitative Assessment of the Reporting Quality of Herbal Medicine Research: The Road to Improvement.
    Naumann K
    J Altern Complement Med; 2018 Feb; 24(2):168-181. PubMed ID: 28915066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recursive cumulative meta-analysis: a diagnostic for the evolution of total randomized evidence from group and individual patient data.
    Ioannidis JP; Contopoulos-Ioannidis DG; Lau J
    J Clin Epidemiol; 1999 Apr; 52(4):281-91. PubMed ID: 10235168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-analysis and epidemiologic studies in drug development and postmarketing surveillance.
    Temple R
    JAMA; 1999 Mar; 281(9):841-4. PubMed ID: 10071007
    [No Abstract]   [Full Text] [Related]  

  • 35. Meta-analyses of clinical drug trials--gold standard reviews or statistical alchemy?
    Chan ES
    Ann Acad Med Singap; 2000 Sep; 29(5):610-5. PubMed ID: 11126696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of meta-analyses in assessing cancer treatments.
    Sylvester R; Collette L; Duchateau L
    Eur J Cancer; 2000 Jul; 36(11):1351-8. PubMed ID: 10899647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. When a randomised controlled trial is needed to assess drug safety. The case of paediatric ibuprofen.
    Mitchell AA; Lesko SM
    Drug Saf; 1995 Jul; 13(1):15-24. PubMed ID: 8527016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized clinical trials and observational studies in the assessment of drug safety.
    Sawchik J; Hamdani J; Vanhaeverbeek M
    Rev Epidemiol Sante Publique; 2018 May; 66(3):217-225. PubMed ID: 29685700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meta-analyses of randomised controlled trials.
    Davey Smith G; Egger M
    Lancet; 1997 Oct; 350(9085):1182. PubMed ID: 9343537
    [No Abstract]   [Full Text] [Related]  

  • 40. Meta-analyses of randomised controlled trials.
    Rothwell PM; Robertson G
    Lancet; 1997 Oct; 350(9085):1181-2. PubMed ID: 9343536
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.